Lonza jumps 3.8% after Sfr2.25bn rights issue wins approval from shareholders

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Lonza jumps 3.8% after Sfr2.25bn rights issue wins approval from shareholders

Shares in Lonza, the Swiss pharmaceutical company, closed 3.8% higher on Wednesday after it launched its Sfr2.25bn rights issue to partly finance its acquisition of Capsugel from KKR, having secured approval from its shareholders at its annual general meeting on Tuesday.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article